ACTG

Studies/Projects
Publications
Presentations

A5300B/I2003B: Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx)

Post Date:

2019-08-19

|

Countries:

|

Clinical Sites:

Dr. Amita Gupta is Protocol Co-chair for this multinational clinical trial. BACKGROUND The World Health Organization (WHO) estimates that there were 480,000 incident cases of MDR-TB globally in 2015. MDR-TB has been shown to be almost twice as common in TB patients living with HIV compared with TB...

A5300B/I2003B: Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx)

Post Date:

2019-08-19

|

Countries:

|

Clinical Sites:

Dr. Amita Gupta is Protocol Co-chair for this multinational clinical trial. BACKGROUND The World Health Organization (WHO) estimates that there were 480,000 incident cases of MDR-TB globally in 2015. MDR-TB has been shown to be almost twice as common in TB patients living with HIV compared with TB...

A5302: BioBank for Surrogate Marker Research for TB (B-SMART)

Post Date:

2017-11-21

|

Countries:

|

Clinical Sites:

This study is conducted under the AIDS Clinical Trials Group (ACTG) and funded by the U.S. National Institutes of Health. A5302 is a multi-center trial of the AIDS Clinical Trials Group (ACTG) in collaboration with the Tuberculosis Trials Consortium (TBTC).This study will be conducted at the BJ...

A5332: Randomized Trial to Prevent Vascular Events in HIV – REPRIEVE

Post Date:

2017-06-09

|

Countries:

|

Clinical Sites:

This study is conducted under the AIDS Clinical Trials Group (ACTG) and funded by the U.S. National Institutes of Health. This is a prospective, double-blind, randomized, placebo-controlled, multicenter efficacy study in 6500 subjects, with individual subjects to be followed for up to 72 months...

A5349: Rifapentine-containing Treatment Shortening Regimens for Pulmonary Tuberculosis: A Randomized, Open-label, Controlled Phase 3 Clinical Trial

Post Date:

2017-06-05

|

Countries:

|

Clinical Sites:

This study is conducted under the AIDS Clinical Trials Group (ACTG) and funded by the U.S. National Institutes of Health. This is an international, multicenter, randomized, controlled, open-label, 3-arm, phase 3 non-inferiority trial. Primary Objectives: To evaluate the efficacy of a rifapentine-...

A5300/IMPAACT2003: Study of MDR TB Cases and Their Household Contacts: Operational Feasibility to Inform PHOENIx Trial Design

Post Date:

2015-09-01

|

Countries:

|

Clinical Sites:

This clinical trial was terminated July 18, 2017. It was a study conducted under both the AIDS Clinical Trial Group (ACTG) and the the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network, and funded by the U.S. National Institutes of Health. Dr. Amita Gupta was...

A5290: A Randomized, Phase 2b Study of a Double-Dose Lopinavir/Ritonavir-Based Antiretroviral Regimen with Rifampin-Based Tuberculosis Treatment versus a Standard-Dose Lopinavir/Ritonavir-Based Antiretroviral Regimen with Rifabutin-Based Tuberculosis...

Post Date:

2015-07-07

|

Countries:

|

Clinical Sites:

This study was terminated February 23, 2016; it was conducted under the AIDS Clinical Trials Group (ACTG) and funded by the U.S. National Institutes of Health.. Full Title: A5290, A Randomized, Phase 2b Study of a Double-Dose Lopinavir/Ritonavir-Based Antiretroviral Regimen with Rifampin-Based...

A5279: Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-infected Individuals with Latent Tuberculosis Infection

Post Date:

2014-06-30

|

Countries:

|

Clinical Sites:

This study ended April 27, 2015; it was conducted under the AIDS Clinical Trials Group (ACTG) and funded by the U.S. National Institutes of Health. Dr. Amita Gupta was Protocol Co-Vice Chair for this multinational clinical trial being conducted in Botswana, Brazil, Haiti, Kenya, Malawi, Peru,...

A5288: MULTIOCTAVE, Management Using the Latest Technologies in Resource-limited Settings to Optimize Combination Therapy After Viral Failure

Post Date:

2012-07-16

|

Countries:

This study was terminated in March 2020. It was a mult-country clinical trial conducted in Brazil, Haiti, India, Kenya, Malawi, Peru, South Africa, Thailand, Uganda, and Zambia under the AIDS Clinical Trials Group (ACTG) and funded by the U.S. National Institutes of Health. A5288 is a multi-step,...

A5273: Multicenter Study of Options for Second-Line Effective Combination Therapy (SELECT)

Post Date:

2011-05-12

|

Countries:

|

Clinical Sites:

This study was terminated May 2, 2017; it was conducted under the AIDS Clinical Trials Group (ACTG) and funded by the U.S. National Institutes of Health. This was a multinational clinical trial conducted in Brazil, India, Kenya, Malawi, Peru, South Africa, Tanzania, Thailand, and Zimbabwe. The...

A5282: A Randomized, Phase II Trial to Compare an HPV Test-and-Treat Strategy to a Cytology-Based Strategy for Prevention of CIN 2+ in HIV-Infected Women

Post Date:

2011-03-15

|

Countries:

Indo-JHU partnership work on this trial was officially terminated September 10, 2018; it was conducted under the AIDS Clinical Trials Group (ACTG) and funded by the U.S. National Institutes of Health. This multi-country trial is being conducted in Botswana, Haiti, India, Malawi, Peru, South Africa...

A5225: Phase I/II Dose-Finding Study of High-Dose Fluconazole Treatment in AIDS-Associated Cryptococcal Meningitis

Post Date:

2009-04-22

|

Countries:

|

Clinical Sites:

This trial was terminated in March 2015; it was conducted under the AIDS Clinical Trials Group (ACTG) and funded by the U.S. National Institutes of Health. This multi-country study was conducted in India, Kenyam Peru, South Africa, Thailand, Uganda, United States, and Zimbabwe. A5225/HiFLAC is a...

Impact of Malnutrition on HIV Treatment Failure in Resource-limited Settings

Post Date:

2009-04-02

|

Countries:

|

Clinical Sites:

This study, NWCS 319, was terminated August 20, 2019. Highly active antiretroviral therapy (HAART) has reduced morbidity and mortality among HIV-infected persons worldwide. However, early treatment failure (i.e. WHO stage 3 or 4 illnesses or death during the first 24 months of HAART) is more than 3...

A5207: Maintaining Options for Mothers Study (MOMS): A Phase II Randomized Comparison of Three Antiretroviral Strategies Administered for 7 or 21 Days to Reduce the Emergence of Nevirapine Resistant HIV-1 Following a Single Intrapartum Dose of Nevirapine

Post Date:

2004-12-20

|

Countries:

This study was terminated January 16, 2014; it was conducted under the AIDS Clinical Trials Group (ACTG) and funded by the U.S. National Institutes of Health. A major disadvantage of giving SD NVP is the potential for maternal development of NVP resistance and additional resistance to other...

A5175: PEARLS Evaluation of the Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor- Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Individuals

Post Date:

2004-07-27

|

Countries:

Full Title: A Phase IV, Prospective, Randomized, Open-Label Evaluation of the Efficacy of Once-Daily Protease Inhibitor and Once Daily Non-Nucleoside Reverse Transcriptase Inhibitor Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Individuals from Resource-Limited Settings (...

One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis

Post Date:

2019-03-14

Publication:

New England Journal of Medicine

Exciting findings from A5279: One month of Rifapentine with isonaizid is as effective as a 9-month course of isoniazid alone!

Prevalence and Incidence of Tuberculosis Infection and Disease Among Household Contacts Exposed to Rifampin-resistant/Multidrug resistant Tuberculosis (RR/MDR-TB)

Post Date:

2020-07-08

Gupta A, Wu X, Kim S, Naini L, Hughes M, Dawson R, Gaikwad S, Sanchez J, Mendoza A, Smith B, Shah S, Hesseling A, Churchyard G, Swindells S for the ACTG/IMPAACT PHOENIx feasibility study team. Prevalence and Incidence of Tuberculosis Infection and Disease Among Household Contacts Exposed to...

Resistance to Mycobacterium tuberculosis infection among household contacts of MDR TB patients

Post Date:

2019-10-31

|

Countries:

|

Clinical Sites:

Baliashvili D , Gandhi NR, Kim S, Gupta A, Churchyard G, Swindells S, Hesseling A, Hughes M, Shah S for the ACTG 5300/IMPAACT I2003 PHOENIx Feasibility Study Team. Resistance to Mycobacterium tuberculosis infection among household contacts of MDR TB patients. Poster presentation. 50th Union World...

High prevalence of tuberculosis infection in children living in households of MDR-TB patients

Post Date:

2019-10-31

|

Countries:

|

Clinical Sites:

Kim S , Wu X, Hughes M, Mendoza-Ticona A, Churchyard G, Swindells S, Shah NS, Gupta A, Hesseling A for the A5300/I2003 PHOENIx Feasibility Study Team. High prevalence of tuberculosis infection in children living in households of MDR-TB patients. Short oral presentation. 50th Union World Conference...